Best 4-in-1 ED Medication: Every Multi-Ingredient Treatment, Compared

Several telehealth companies now sell a "4-in-1" erectile dysfunction formula, and one of them advertises itself as the world's first and only — despite two competitors selling four-ingredient formulas of their own. That alone should tell you how much of this category is marketing. Here is what is actually in each product, what each costs, which companies tell you your dose, and why counting ingredients is close to the worst way to pick.

All Five Multi-Ingredient ED Treatments, Side by Side

Five products dominate searches for combination ED treatment. Three genuinely contain four distinct ingredients aimed at sexual function, one contains three, and one isn't a single product at all. The whole field, current as of July 2026:

Two things in that table deserve flagging before we go further, because they are the two facts most often reported wrong.

First, "Hims Hard Mints" is not one product. As of July 2026, Hims sells Hard Mints as a family of four distinct compounded formulations: Tadalafil Hard Mints, Vardenafil Hard Mints, Tadalafil + Vardenafil Hard Mints, and Sildenafil + Tadalafil Hard Mints. The most complex has two active ingredients. Any comparison that puts "Hard Mints" in a row beside a four-ingredient formula, as though there were one Hard Mint with one recipe, is comparing against something that doesn't exist. Before you compare Hard Mints to anything, you have to say which one.

Second, more than one product here is a real 4-in-1. Strut Health markets Super Strut as the world's first and only 4-in-1 ED tablet. BlueChew Gold has four ingredients. MEDVi QUAD has four ingredients. Whoever tells you their product is the only one of its kind is wrong, and it doesn't matter which of them is saying it — we won't make that claim on QUAD's behalf either.

What "4-in-1" Actually Means — and Why the Count Misleads

Here is the honest core of this page, and it argues against the search you probably ran to get here.

"4-in-1" counts ingredients, and ingredients aren't what determines whether a formula does something a cheaper drug can't. What matters is how many distinct biological mechanisms a formula covers, and how strong the evidence is behind each. A raw count answers neither question.

Consider two hypothetical 4-in-1s. One contains four PDE5 inhibitors. The other contains one PDE5 inhibitor plus three ingredients acting on desire, nerve signalling, and nitric oxide. Both get to say "4-in-1." Only the second broadens what the medication actually does. Stacking drugs from one class mostly stacks that class's side effects.

Now look at the real products. Super Strut is two PDE5 inhibitors (tadalafil, vardenafil) plus two non-PDE5 ingredients (apomorphine, oxytocin). BlueChew Gold is two PDE5 inhibitors (sildenafil, tadalafil) plus the same two. MEDVi QUAD is two PDE5 inhibitors, one nitric-oxide precursor (L-citrulline), and one central desire agent (PT-141). All three are 4-in-1s taking slightly different routes, and those differences are more interesting than the number four.

The Hims "3-in-1" is a good illustration of the problem

Hims sells a 3-in-1 offering, and the intuitive read is that it contains three ED drugs. It doesn't. The formula is sildenafil, tadalafil, and vitamin B12. The third ingredient is a vitamin.

That isn't a scandal, and it isn't a criticism of the product — sildenafil plus tadalafil is a sound combination and Hims prices it aggressively, from $30 per month. But it demolishes the arithmetic that treats a 3-in-1 as three-quarters of a 4-in-1. Functionally, Hims' 3-in-1 is a two-drug formula with a vitamin in it. If you were mentally ranking these products by ingredient count, that single fact should reorder your list.

Also worth saying: more may not be what you need

Hims sells FDA-approved generic sildenafil from $22 per month and generic tadalafil from $24 per month. If a plain generic already works for you, a four-ingredient compounded formula at $67 to $119 per month is buying mechanisms you aren't using, plus the side effects that come with them. The case for a multi-ingredient formula only gets strong when a single PDE5 inhibitor has genuinely underperformed, or when the problem isn't purely mechanical — which brings us to the mechanisms.

The Mechanisms: Blood Flow Versus Desire

Everything in this category falls into one of three buckets, and knowing which bucket each ingredient sits in tells you more than any product page will.

Bucket 1: PDE5 inhibitors — the blood-flow drugs

Sildenafil, tadalafil, and vardenafil — the most studied ED drugs in existence and the backbone of every product on this page. They work downstream in the nitric-oxide pathway, preventing the breakdown of the signal that keeps blood vessels dilated. They do not create desire. If the brain isn't sending the signal, a PDE5 inhibitor has nothing to amplify.

They differ from each other in timing rather than in kind: sildenafil peaks early with a 4-to-6-hour window, tadalafil hits less sharply but persists up to 36 hours. Combining two is a pharmacokinetic decision, not a mechanistic one — a broader time window, not a broader mechanism. Every four-ingredient product here contains two of them, so on this bucket they're close to equivalent.

Bucket 2: L-citrulline — the supply side of the same pathway

Only MEDVi QUAD includes this. L-citrulline is an amino acid, not a drug. The body converts it to L-arginine, which raises nitric-oxide production, which supports vessel dilation — the same pathway the PDE5 inhibitors act on, approached from the opposite end. L-citrulline works on supply; PDE5 inhibitors stop the signal being dismantled downstream.

The evidence is real but small: a single-blind study of 24 men with mild ED (Cormio et al., Urology, 2011) found erection hardness improved in 50% of men versus 8% on placebo. Twenty-four men is a small trial, and this is a supplement-grade ingredient rather than an FDA-approved ED drug. A modest supporting player, not a reason to choose or reject a product.

Bucket 3: the desire and arousal ingredients — where products actually differ

This is the interesting bucket, and it splits the field cleanly. Three different molecules are in play, on three different receptor systems.

Read that table carefully, because it's where the honest differences live.

Apomorphine has the strongest ED-specific evidence of the three. It is not a filler ingredient and we won't pretend otherwise — it has published clinical evidence in erectile dysfunction and a genuine history of use. Its practical drawback is nausea, which it is strongly associated with. QUAD removed apomorphine in July 2026; MEDVi's stated reason was taste, which it says improves approval rates during consultation. MEDVi hasn't publicly said anything apomorphine-specific beyond that, so we won't speculate, and the fact that Super Strut, BlueChew Gold, and Rugiet Ready still contain it is not a strike against them.

Oxytocin is the weakest link in this bucket. Both Super Strut and BlueChew Gold include it sublingually — the route the published pharmacokinetic work found unreliable, at about 4.5% bioavailability with ten-fold variation between people. There are no published randomised trials of oxytocin for ED at all. It may do something for some people; nobody has shown it. Paying a premium for an oxytocin-containing formula means paying for the least substantiated ingredient in the category.

PT-141 is the pathway nobody else uses. This is MEDVi QUAD's one genuine structural advantage, and it's worth stating precisely. PT-141 acts on melanocortin receptors centrally, on desire and arousal, not on blood flow. It has an FDA approval — as Vyleesi, at 1.75 mg subcutaneous injection, for low sexual desire in premenopausal women. It is not approved for ED and not approved in men. Early-phase intranasal trials in men did show erectogenic effects, including in some sildenafil non-responders, but that development programme was halted, partly over blood-pressure concerns. Its use in QUAD is compounded, off-label, and prescriber-supervised. A genuinely different bet from apomorphine and a better-evidenced one than oxytocin — but a bet.

One more thing about PT-141 that gets missed: it produces a transient increase in blood pressure and is contraindicated in uncontrolled hypertension and known cardiovascular disease. PDE5 inhibitors lower blood pressure. A formula containing both pulls in two directions at once — a real reason the prescribing clinician needs your cardiovascular history. Our full PT-141 explainer covers approval status, the correct dosing range, and the side effect data, including why the ~20 mg figures circulating online are wrong by roughly a factor of ten.

All of These Are Compounded, and None Is FDA-Approved

This section applies with exactly equal force to every product on this page, including the one we link to.

Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they reach patients. That is true of MEDVi QUAD, and of BlueChew Gold, Super Strut, Rugiet Ready, and every Hard Mints formulation. Sildenafil and tadalafil are FDA-approved as individual drugs — the combinations you're buying are not.

Two of these companies say so plainly on their own sites, which is to their credit. Hims states verbatim that "Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA." Strut Health states that its compound is not FDA tested or approved and that the use is off-label.

The 503A / 503B distinction, and why it matters

Not all compounding is regulated the same way, and the difference is worth understanding because marketing copy in this category tends to blur it.

503A compounding is done by a licensed pharmacy or physician, primarily under state regulation, against a patient-specific prescription. 503A compounders are exempt from CGMP — Current Good Manufacturing Practice, the federal manufacturing quality standard.

503B outsourcing facilities register with the FDA and are subject to CGMP. That is a meaningfully higher bar on manufacturing quality.

If consistency of what's in the bottle matters to you — and with a four-ingredient formula it should — asking which pathway a company's pharmacy operates under is a better question than asking how many ingredients are in the product. None of these companies answers it prominently.

None of this makes compounding illegitimate. The FDA recognises that it serves real medical needs — allergies to an excipient in a commercial product, dosage forms nobody manufactures. A sublingual liquid containing several actives can only exist as a compound. Read this as a disclosure, not a condemnation. What it means practically is that the efficacy and safety claims on every product page in this category are unvetted by a regulator, and the burden of judgement sits with you and your prescriber.

Dose Transparency: Who Tells You What You're Taking

This is where the field separates sharply, and where the most expensive product does not win.

Super Strut publishes exact strengths for every ingredient in every tier. Not a range, not "personalised" — actual numbers, on Strut Health's own site, before you pay:

Strut caps use at one dose daily and includes shipping, the online medical visit, and follow-up, with auto-refill you can cancel. Its own FAQ also notes a practical catch: the tablets soften or melt above roughly 70°F and should be refrigerated. That's the same weakness we've raised about Rugiet Ready's troches — a characteristic of fast-dissolving sublingual tablets rather than a defect unique to Strut — but if you travel or live somewhere hot, plan for it.

MEDVi publishes no strengths for QUAD at all. The dose is described as set by the prescribing physician during consultation. That's a defensible way to run a compounded product and genuinely how compounding is meant to work — but it means you can't see what you're buying before you buy it, and Super Strut proves being compounded doesn't force that outcome. Strut wins this comparison outright and we're not going to soften it.

Hims publishes no strengths either. The company describes Hard Mints doses as personalised. Milligram figures for Hard Mints do circulate on affiliate blogs, but they contradict each other and none cites Hims, so we don't repeat them. We won't print a number Hims hasn't published.

Ranked on this one axis: Super Strut first by a wide margin, Rugiet Ready second on the strength of published tiering, then BlueChew Gold, QUAD, and Hims all effectively tied at the bottom. If knowing your exact dose before you pay is your priority, that ranking is your answer and you can stop reading.

Which One Fits Which Person

No head-to-head trial exists between any two products on this page. Nobody — including us — can tell you which is most effective, and anyone who claims a winner on efficacy is making it up. What follows is matching, not ranking.

If price is the constraint: Hims

Hims wins on cost decisively and there's no honest way around it. Its 3-in-1 starts from $30 per month and Daily Hard Mints (tadalafil) from $39 per month, with per-use options from $6 per use — all carrying the caveat that actual price depends on product and plan. Against QUAD's $119, that isn't a close call. Hims will also sell you FDA-approved generics for less still: sildenafil from $22 per month, tadalafil from $24. If you haven't yet established that a single PDE5 inhibitor fails you, the cheap generic is the rational first step, not a four-ingredient compound. The trade-offs: no published strengths, a Hard Mints line that tops out at two active ingredients per formulation, and no fast-onset claim — Hims says tadalafil works "in as little as 30 minutes" and lasts up to 36 hours.

If you want to know exactly what you're taking: Super Strut

Strut Health is the only company here that lets you read the full formula, ingredient by ingredient, before paying — and at $79 to $99 per month for 10 tablets it undercuts QUAD while doing it. It also gives you two non-PDE5 mechanisms (apomorphine and oxytocin) against QUAD's one, though one of that pair is the poorly-absorbed oxytocin. On speed, Strut claims onset in as little as 15 minutes with a 15-to-30-minute range in its FAQ and activity up to 36 hours; MEDVi claims roughly 10 to 15 minutes for QUAD. Both are company statements rather than trial data and the ranges overlap almost entirely, so treat onset as a tie and let the published milligrams decide. Refrigeration is the real cost of choosing Strut.

If you want PT-141 specifically: MEDVi QUAD

This is QUAD's actual edge, and it's narrower and more specific than its marketing suggests. PT-141 is a melanocortin pathway no other product here touches — not Super Strut, not BlueChew Gold, not Rugiet Ready, not Hims — with human trial data in men and an FDA approval in a different indication, which puts it on firmer ground than oxytocin. If a PDE5 inhibitor has already given you good blood flow and the missing piece is desire, that's the case for paying $119 rather than $79. In return you accept the highest price in the category, no published doses, off-label use of a drug whose ED development was halted partly over blood-pressure concerns, and a first-dose nausea risk the Vyleesi data suggests could be significant. Our full MEDVi QUAD review covers the formula, pricing, and cancellation terms, and our piece on the apomorphine removal explains what changed in July 2026.

If you want the cheapest genuine four-ingredient formula: BlueChew Gold

Roughly $67 or more per month for sildenafil, tadalafil, apomorphine, and oxytocin — three of which have ED evidence behind them, with the oxytocin effectively a bonus rather than something you're paying a premium for. That's about $52 a month cheaper than QUAD on the same PDE5 base. Our QUAD vs BlueChew Gold comparison works through the trade-off ingredient by ingredient.

If you want the longest track record: Rugiet Ready

Rugiet is the three-ingredient option and the most established of the sublingual combinations: sildenafil, tadalafil, and apomorphine, all three with genuine ED evidence, at $80 to $140 per month for 6 doses depending on strength. Fewer ingredients, but nothing speculative in it — a defensible position if unproven additions make you uneasy. The troche's melting problem above 70°F is the recurring complaint. Our Rugiet Ready review has the full breakdown.

Frequently Asked Questions

Related